Though Gilead Sciences made waves last June with a landmark FDA approval for its twice-yearly HIV preventative Yeztugo (lenacapavir), the first-in-class drug had previously been used as a long-acting treatment for the viral infection. Now, Gilead has conducted an analysis
read moreViking Therapeutics and Aspen Neuroscience have both stepped up their commercialization planning, each tapping leaders with resumes spanning the likes of Amgen, Eli Lilly, Merck and GSK to oversee launch preparations for their obesity and Parkinson’s hopefuls. More: Viking enlists
read moreThe FDA is apparently not charmed by the mischievous “Lipid Lurkers” in an Esperion Therapeutics commercial for cholesterol-lowering drug Nexlizet. More: FDA untitled letter skewers Esperion’s claims about cholesterol med Nexlizet in TV ad Source: fierce
read moreUnder the agreement, Genesis is responsible for marketing Daiichi’s 2023-approved acute myeloid leukemia med Vanflyta in 13 European countries. More: Daiichi taps Genesis to handle commercialization of leukemia med Vanflyta in 13 European countries Source: fierce
read moreTwo investigational cardiometabolic drugs from Eli Lilly stand out in Clarivate’s annual Drugs to Watch report. Johnson & Johnson also has two drugs featured on the data analytics company’s 2026 list. More: Lilly's prospective cardiometabolic launches dominate list of drugs
read moreForget about Herceptin. There’s a new HER2 agent that ought to be used in HER2-positive stomach cancer, and that’s Jazz Pharmaceuticals’ bispecific Ziihera—at least according to two experts. More: Jazz touts Ziihera as the new HER2 agent of choice in
read more© 1994 - 2026 B.M. Pharmaceuticals